There is no single test that tells you which heart procedure you need. The decision comes from a Heart Team, a cardiologist and cardiac surgeon reviewing your anatomy, your heart’s pumping strength, and your overall surgical risk together. That said, the criteria below are the same ones your cardiologist is working from, drawn from the 2021 ACC/AHA/SCAI coronary revascularization guideline and the 2020 ACC/AHA valve disease guideline, so you can walk into your consultation already knowing what questions matter.
The three questions your Heart Team is actually answering
Before “angioplasty, bypass, or TAVR,” your team is really asking three things:
- What is blocked or damaged, and where? A single narrowed artery is a different problem than three narrowed arteries or a diseased heart valve.
- How well is your heart pumping? Your ejection fraction (EF) changes which procedure carries the better long-term survival odds.
- How much surgical risk can your body tolerate? Age alone is not the deciding factor. Frailty, kidney function, lung disease, and prior surgeries all feed into a formal risk score.
The 2021 guideline formalized this into what it calls a Heart Team approach: a multidisciplinary discussion, not a single doctor’s opinion, for anyone whose best treatment path isn’t obvious.
Candidacy for angioplasty (PCI)
Angioplasty, or percutaneous coronary intervention (PCI), is generally the front-line option when:
- You have a blockage in one or two coronary arteries and normal or near-normal heart pumping function.
- You’re having a heart attack (STEMI or NSTEMI) and need the artery opened fast. Speed is the whole point here: PCI doesn’t require opening the chest, so it can be done within hours of arrival.
- Your anatomy is straightforward enough that a cardiologist can reach the blockage with a catheter and expect a durable result, reflected in a lower SYNTAX score (the scoring system guidelines use to describe how complex and spread out the blockages are).
What tends to disqualify PCI as the primary option: left main coronary artery disease, three-vessel disease combined with diabetes, or anatomy too complex or calcified for a catheter-based fix. In these situations, the guideline consistently favors sending the case to the Heart Team to weigh CABG instead.
Candidacy for bypass surgery (CABG)
CABG remains what the guideline calls a Class 1 recommendation, meaning the evidence and expert agreement are both strong, in two specific situations:
- Left main coronary artery disease. This is the artery that feeds most of the heart muscle, so blockages here are treated more aggressively.
- Reduced ejection fraction (EF ≤35%) with significant coronary disease. The long-term survival data here, from the STICH trial extension, still favors surgery over medication alone in this group.
CABG is also frequently the stronger option for three-vessel disease, particularly when diabetes is present, largely because bypass grafts tend to hold up better than stents across multiple diseased segments over the long run.
What tends to disqualify CABG: prohibitive surgical risk (assessed with the Society of Thoracic Surgeons, or STS, risk score), targets too small or too diseased to graft onto, or a patient whose overall frailty means the risks of open-heart surgery and recovery outweigh the anticipated benefit.
One honest note worth knowing before your consultation: the 2021 guideline actually downgraded CABG’s recommendation strength for stable multivessel disease with normal EF, from a Class 1 to a Class 2b (meaning “may be considered” rather than “should be done”), a change some cardiac surgery societies have publicly disputed as not fully supported by the underlying trial data. If your case falls into that specific group, normal pumping function with multivessel disease, it’s worth asking your Heart Team directly how they weighed that particular recommendation.
Candidacy for TAVR (transcatheter aortic valve replacement)
TAVR is a valve procedure, not an artery procedure, used for severe aortic stenosis (a narrowed aortic valve). The 2020 ACC/AHA valve guideline lays out an age- and risk-based framework:
- Under 65: surgical valve replacement (SAVR) is generally recommended over TAVR.
- 65 to 80: either SAVR or transfemoral TAVR is considered appropriate, decided jointly with the patient.
- Over 80, or life expectancy under 10 years: TAVR is the Class 1 recommendation.
- Any age with high or prohibitive surgical risk: TAVR is preferred, provided predicted survival after the procedure is more than 12 months with an acceptable quality of life.
To even be considered symptomatic and severe enough for either procedure, most trial and guideline criteria require an aortic valve area of 1.0 cm² or smaller, and a mean pressure gradient across the valve of 40 mmHg or higher (or a peak jet velocity of 4.0 m/s or higher) on echocardiogram.
What tends to disqualify TAVR: predicted survival under 12 months regardless of the procedure, vascular access too narrow or diseased for the delivery catheter, or valve anatomy unsuited to a transcatheter device (your echo and CT will show this). In those situations, the guideline authors are explicit that palliative, symptom-focused care is a reasonable and legitimate path rather than pushing forward with intervention.
Frequently asked questions
Can I choose which procedure I want? Your preference matters and is formally part of the decision, informed consent guidelines call for shared decision-making, but it works within the boundaries of what your anatomy and risk profile safely allow. A cardiologist should walk you through the tradeoffs of each option that is medically appropriate for your case.
Does age alone disqualify me from surgery? No. The guidelines use a combination of frailty, organ function, and a formal risk score, not age on its own, though age is one input into those calculations.
What if my cardiologist and surgeon disagree? That’s exactly what the Heart Team discussion is for. Disagreement between specialists on a borderline case is normal and is a sign the discussion is being taken seriously, not a red flag.
The honest limit here
Guidelines describe what tends to work best across large groups of patients studied in trials. They are not a substitute for your specific case being reviewed by a Heart Team that has seen your actual angiogram, echocardiogram, and health history. Nothing in this article, or in any online symptom checker, can tell you which procedure you personally need. It can only prepare you to have a more informed conversation about it.
If you’ve been told you may need one of these procedures and want a second set of eyes on your case, get a second opinion with us
Sources
- American College of Cardiology, Key Takeaways From the 2021 Coronary Revascularization Guidelines — https://www.acc.org/Latest-in-Cardiology/Articles/2022/10/31/13/02/Key-Takeaways-From-the-2021-Coronary-Revascularization-Guidelines
- Journal of the American College of Cardiology, 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization — https://www.jacc.org/doi/10.1016/j.jacc.2021.09.006
- American Heart Association / Circulation, 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization, Executive Summary — https://www.ahajournals.org/doi/10.1161/CIR.0000000000001039
- American College of Cardiology, 2020 ACC/AHA Heart Valve Disease Guideline: Key Perspectives, Part 1 — https://www.acc.org/latest-in-cardiology/ten-points-to-remember/2020/12/16/21/58/2020-acc-aha-vhd-gl-pt-1-gl-vhd
- Cleveland Clinic ConsultQD, Perspectives on the 2020 ACC/AHA Guideline for Valvular Heart Disease — https://consultqd.clevelandclinic.org/perspectives-on-the-2020-acc-aha-guideline-for-valvular-heart-disease-focus-on-the-aortic-valve
- PMC / Brazilian Society of Cardiovascular Surgery, Official Scientific Statement on the 2021 ACC/AHA/SCAI Guideline (discussion of the CABG recommendation downgrade) — https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11025289/
